US 11,958,889 B2
Compositions of phosphorylated tau peptides and uses thereof
Elizabeth Anne Ramsburg, Chalfont, PA (US); Donata de Marco, Turnhout (BE); Charlotte Sadaka, San Diego, CA (US); Jaap Goudsmit, Amsterdam (NL); Andreas Muhs, Cugy (CH); Maria Pihlgren Bosch, Mont-sur-Lausanne (CH); Marija Vukicevic Verhille, St-Sulpice (CH); David Hickman, St-Sulpice (CH); Nicolas Piot, Grandvaux (CH); and Saroj Raj Ghimire, Chavannes-Pres-Renens (CH)
Assigned to Janssen Pharmaceuticals, Inc., Titusville, NJ (US); and AC Immune SA, Lausanne (CH)
Appl. No. 16/757,621
Filed by Janssen Pharmaceuticals, Inc., Titusville, NJ (US); and AC Immune SA, Lausanne (CH)
PCT Filed Oct. 24, 2018, PCT No. PCT/US2018/057286
§ 371(c)(1), (2) Date Apr. 20, 2020,
PCT Pub. No. WO2019/084118, PCT Pub. Date May 2, 2019.
Claims priority of provisional application 62/577,157, filed on Oct. 25, 2017.
Prior Publication US 2020/0376078 A1, Dec. 3, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); A61K 9/127 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61P 25/28 (2006.01)
CPC C07K 14/4711 (2013.01) [A61K 9/127 (2013.01); A61K 9/1271 (2013.01); A61K 38/1709 (2013.01); A61K 39/0007 (2013.01); A61K 39/39 (2013.01); A61P 25/28 (2018.01); A61K 2039/55516 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/6018 (2013.01); A61K 2039/627 (2013.01)] 24 Claims
OG exemplary drawing
 
1. A liposome, comprising:
a. a tau peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 5, 9, and 12, wherein the tau peptide is presented on the surface of the liposome;
b. a helper T cell epitope comprising at least one amino acid sequence selected from the group consisting of: SEQ ID NOs:23, 24, 25, and 26;
c. a lipidated CpG oligonucleotide, wherein the CpG oligonucleotide comprises one or more phosphorothioate internucleotide linkages, and wherein the CpG oligonucleotide is covalently linked to at least one cholesterol via a linker; and
d. monophosphoryl lipid A (MPLA).